Medicines For Europe Country Specific Market Access Policies

24 May 2018

Policy

Positioning Statements on Physician-led Switching for Biosimilar Medicines

27 April 2018

Policy

Positioning Statements on Physician-led Switching for Biosimilar Medicines BIOSIMILAR MEDICINES […]

IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)

20 April 2018

Policy

Life Science Industry Coalition Position paper

14 December 2017

Policy

Joint statement – European health community calls on the EU and UK to prioritise patients as crunch Article 50 decision approaches

7 December 2017

Policy

Today a group of organisations representing patients, healthcare professionals and […]

Position Paper: for an ambitious EU industrial strategy

24 October 2017

Policy

SPC manufacturing waiver

24 October 2017

Policy

SME Intergroup Conclusions – Boosting SMEs through the SPC Waiver […]

Position Paper Medicines Shortages

29 September 2017

Policy

Position paper Reading list Report Address medicine shortages in Europe

Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

13 July 2017

Policy

Medicines for Europe Director General Adrian van de Hoven participated […]